Exact Sciences (EXAS) Enrolls First Patient in Pivotal MCED Study
Exact Sciences (EXAS) initiates the MCED Falcon Registry study, with Baylor Scott & White Health and Endeavor Health serving as…
86,835€
0,65%
Echtzeit-Aktienkurs Exact Sciences Corp.
Bid:
Ask:
Nachrichten zur Exact Sciences Corp. Aktie
Exact Sciences (EXAS) Rides on Cologuard Sales, New Launches
Exact Sciences (EXAS) identifies more than 100 opportunities with payers and health systems to address the care gaps with Cologuard…
Exact Sciences: Cost Optimization And Product Strength
…
Why You Should Add Exact Sciences (EXAS) to Your Portfolio
Exact Sciences (EXAS) progress with strategic priority and strong solvency bode well.…
Exact Sciences (EXAS) Q2 2024 Earnings Call Transcript
EXAS earnings call for the period ending June 30, 2024.…
Exact Sciences (EXAS) Q2 Loss Narrower Than Expected, Sales Beat
Exact Sciences (EXAS) second-quarter 2024 top-line results reflect robust revenues from the Screening and Precision Oncology segments.…
Exact Sciences: Still No Reason To Own
…
Exact Sciences (EXAS) Witnesses Rising Expenses, Competition
Exact Sciences (EXAS) has numerous competitors, given the large market for colorectal cancer screening.…
Exact Sciences (EXAS) to Showcase Favorable Research Outcome
Exact Sciences (EXAS) latest study research result shows commitment to innovation and strategies that expand access to effective cancer screening…
ASCO®: Exact Sciences bekräftigt mit mehreren Datenpräsentationen seine langfristige Vorreiterrolle in der Krebsfrüherkennung und bei der Verbesserung von Behandlungsergebnissen
MADISON, Wisconsin--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), ein führender Anbieter von Krebsfrüherkennungs- und Diagnosetests, wird auf der Jahrestagung der American…
Exact Sciences stock drops as Guardant Health test supported by FDA panel By Investing.com
Exact Sciences stock drops as Guardant Health test supported by FDA panel…
Exact Sciences (EXAS) Q1 2024 Earnings Call Transcript
EXAS earnings call for the period ending March 31, 2024.…
Exact Sciences Shares Drop 10% on Earnings Miss By Investing.com
Exact Sciences Shares Drop 10% on Earnings Miss…
Should You Buy Exact Sciences (EXAS) Ahead of Q1 Earnings?
Exact Sciences (EXAS) first-quarter 2024 performance is expected to include gains from robust Cologuard uptake and continuing Oncotype DX growth,…
Exact Sciences names Aaron Bloomer as CFO
…
How This CEO Consumerized Cancer Diagnostics Into A $13B Enterprise
A decade ago, Exact Sciences launched Cologuard, impacting the fight against colorectal cancer. Its growth of 7000% is in part…
Exact Sciences EVP sells $140k in company stock By Investing.com
Exact Sciences EVP sells $140k in company stock…
Citi sees Exact Sciences shares climbing after rivals data disappoints By Investing.com
Citi sees Exact Sciences shares climbing after rivals data disappoints…
Exact Sciences (EXAS) Oncoguard Esophagus Test Looks Promising
Exact Sciences (EXAS) advances the development of the non-endoscopic Oncoguard Esophagus test to screen for esophageal cancer and pre-cancer.…
Exact Sciences: Cancer Battle Continues, Shares Likely To Plateau
…
Exact Sciences (EXAS) BLUE-C Study Results Published in NEJM
Exact Sciences (EXAS) announces the publication of the BLUE-C study results in The New England Journal of Medicine.…
Cathie Wood Darling Could Pop On Its Next-Gen Colon Cancer Test
Exact Sciences is hoping to launch an next-generation version of Cologuard in 2025.…
5 Small Biotech ETFs to Watch (Updated 2024)
Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants…